427 related articles for article (PubMed ID: 16469706)
21. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
[TBL] [Abstract][Full Text] [Related]
22. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
23. Membrane-initiated steroid signaling action of estrogen and breast cancer.
Song RX
Semin Reprod Med; 2007 May; 25(3):187-97. PubMed ID: 17447208
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
He D; Falany CN
Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
26. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
[TBL] [Abstract][Full Text] [Related]
28. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
29. CK2 signaling in androgen-dependent and -independent prostate cancer.
Wang G; Ahmad KA; Unger G; Slaton JW; Ahmed K
J Cell Biochem; 2006 Oct; 99(2):382-91. PubMed ID: 16598768
[TBL] [Abstract][Full Text] [Related]
30. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
[TBL] [Abstract][Full Text] [Related]
31. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
Knudsen BS; Miranti CK
J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
[TBL] [Abstract][Full Text] [Related]
32. Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer.
Péant B; Diallo JS; Lessard L; Delvoye N; Le Page C; Saad F; Mes-Masson AM
Mol Cancer Res; 2007 Jan; 5(1):87-94. PubMed ID: 17259348
[TBL] [Abstract][Full Text] [Related]
33. Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine rich tetratricopeptide repeat containing protein alpha.
Buchanan G; Ricciardelli C; Harris JM; Prescott J; Yu ZC; Jia L; Butler LM; Marshall VR; Scher HI; Gerald WL; Coetzee GA; Tilley WD
Cancer Res; 2007 Oct; 67(20):10087-96. PubMed ID: 17942943
[TBL] [Abstract][Full Text] [Related]
34. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Zhang X; Li W; Olumi AF
Clin Cancer Res; 2007 Dec; 13(23):7181-90. PubMed ID: 18056199
[TBL] [Abstract][Full Text] [Related]
35. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
[TBL] [Abstract][Full Text] [Related]
36. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
37. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators.
Härkönen PL; Väänänen HK
Ann N Y Acad Sci; 2006 Nov; 1089():218-27. PubMed ID: 17261769
[TBL] [Abstract][Full Text] [Related]
38. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells.
Heitzer MD; DeFranco DB
Cancer Res; 2006 Jul; 66(14):7326-33. PubMed ID: 16849583
[TBL] [Abstract][Full Text] [Related]
39. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
Chen M; Ni J; Chang HC; Lin CY; Muyan M; Yeh S
Carcinogenesis; 2009 May; 30(5):841-50. PubMed ID: 19126643
[TBL] [Abstract][Full Text] [Related]
40. Receptor mechanisms mediating non-genomic actions of sex steroids.
Boonyaratanakornkit V; Edwards DP
Semin Reprod Med; 2007 May; 25(3):139-53. PubMed ID: 17447204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]